Abstract 849P
Background
Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm that originates from the dendritic cell and manifests as locally advanced disease or multisystem involvement. The overall 5-year survival rate of a person diagnosed with LCH is >90% (100% for patients with single-system disease and 91.7% for patients with multi-system disease). Management of single system or multisystem disease involves a combination of steroids and/or chemotherapy. Utilizing the NCDB, we aim to study the clinical and demographic characteristics of LCH patients who died during the period of 2010-2017.
Methods
A total of 1282 patients diagnosed with LCH in USA above the age of 18 years between 2010 and 2017 were identified utilizing the National Cancer Database (NCDB). Patients were identified with ICD-O-3 morphologic code 9751/3 and data extracted from PUF using SPSS. Demographic factors (Race, gender, facility location & type annual household income, Charlson-Deyo score, age at diagnosis) were studied in relation to patient’s vital status (dead patients). We have excluded people whose vital status was unknown or missing.
Results
Of the 1246 patients diagnosed with LCH between 2010-2017, 951 patients were alive during the entire period and 124 (11.5%) were declared dead in this time frame. Of these, 55% were in the age group less than 60 and 45% >60. 60% received no chemotherapy at all, 24% received single-agent chemotherapy, whereas 6% received multi-agent chemotherapy. Amongst these, 88% were Caucasians and 10% were African Americans. 34% belonged to median income quartile >$63,000, whereas 17% belonged to median quartile income <$40,227. 61% of patient’s had Charlson-Deyo score of 0 whereas 28% had a score of 1.
Conclusions
This is a study identifying the clinical and demographic factors of patients with LCH who were declared dead during the period of 2010-2017. The data shows significant variations in the populations stratified based on age, income quartiles, treatment received and race. These data may provide insight into identifying the factors influencing mortality of patients diagnosed with LCH. The major limitations of our study include no data on specific therapy received, involvement of specific organs, no data on the cause of mortality and age at death.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.